Abstract: Disclosed is a system for delivering an oral care substance to the oral cavity comprising: (a) a delivery composition comprised of: (i) an organosiloxane resin; (ii) a volatile carrier capable of solubilizing the organosiloxane resin; (iii) a rheology modifier; and (iv) at least one oral care substance; and (b) a protective composition comprised of: (i) an organosiloxane resin; and (ii) a volatile carrier capable of solubilizing the organosiloxane resin. Further disclosed is a system for delivering an oral care substance to the oral cavity comprising: (a) a delivery composition comprised of: (i) an organosiloxane resin; (ii) a fluid diorganopolysiloxane-based polymer; (iii) a volatile carrier capable of solubilizing the organosiloxane resin and the fluid diorganopolysiloxane-based polymer; (iv) a rheology modifier; and (v) at least one oral care substance; and (b) a protective composition comprised of: (i) an organosiloxane resin; and (ii) a volatile carrier capable of solubilizing the organosiloxane resin.

Abstract: Disclosed is a composition for delivering an oral care substance to the oral cavity, comprising: (a) an organosiloxane resin; (b) a volatile carrier capable of solubilizing the organosiloxane resin; (c) a rheology modifier; and (d) at least one oral care substance. The present invention is also directed to such compositions comprising: (a) an organosiloxane resin; (b) a fluid diorganopolysiloxane polymer; (c) a volatile carrier capable of solubilizing the organosiloxane resin and the fluid diorganopolysiloxane polymer; (d) a rheology modifier; and (e) at least one oral care substance. Further disclosed is a method of using these compositions.

Abstract: Disclosed are oral compositions comprising: (a) an effective amount of one or more linear polyphosphates having an average chain length of about 4 or more; (b) from about 0.15% to about 5% of a fluoride ion source; (c) from about 0.1% to about 15% of a stannous ion source; (d) an effective amount of a buffering agent; (e) from about 6% to about 70% of an abrasive polishing material containing less than 23% calcium; and (f) from about 40% to about 99% of one or more aqueous carriers; wherein the oral composition has a total water content of from about 1% to about 20%.

Abstract: The present invention relates to a nasal dilator which comprises a means for dilating the nostrils and a thermal element, which can be worn on the nose of a human for an extended period of time, as well as a method of treatment for relief of nasal congestion/blockage, sinus discomfort and pain, and other cold and/or allergy symptoms associated therewith, by applying said nasal dilator to the nose of a human in need of such treatment.

Abstract: The present invention relates to topical aromatic releasing compositions containing one or more volatile aromatic compounds selected from the group consisting of 3-1-menthoxy propane-1,2-diol, N-substituted-p-menthane-3-carboxamides and acyclic carboxamides and mixtures thereof. In further embodiments, these compositions are also useful for providing relief from nasal symptoms.

Abstract: The present invention relates to improved topical pharmaceutical compositions having improved aesthetics which are useful for imparting antimicrobial actives. In particular, it relates to topical moisturizing compositions containing one or more antimicrobial active compounds. These compositions are also useful for providing relief from symptoms associated with, for example, vaginal yeast infections.

Abstract: The present invention relates to improved topical pharmaceutical compositions in the form of a wipe or towelette having improved aesthetics which are useful for imparting antimicrobial actives. In particular, it relates to topical moisturizing wipe compositions containing one or more antimicrobial active compounds. These compositions are also useful for providing relief from symptoms associated with, for example, vaginal yeast infections.

Abstract: The present invention relates to compositions and methods for providing improved treatment, management or mitigation of cold, cold-like, allergy, sinus and/or flu symptoms by administering a safe and effective amount of a composition comprising caffeine and certain pyrrolidine and piperidine ether antihistaminic agents.

Abstract: Oral pharmaceutical compositions in unit dosage form suitable for swallowing (especially capsules) comprising a safe and effective amount of solid Colloidal Bismuth Subcitrate (CBS), and optionally one or more pharmaceutically-acceptable carrier materials, wherein the packing density of the dosage unit is less than about 1 g/ml.

Abstract: Oral pharmaceutical compositions in unit dosage form suitable for swallowing (especially capsules) comprising a safe and effective amount of a soluble bismuth-containing pharmaceutical agent (preferably a pharmaceutically-acceptable salt suitable for oral co-administration of bismuth and an H.sub.2 receptor blocking anti-secretory agent), and optionally one or more pharmaceutically-acceptable carrier materials, wherein the packing density of the dosage unit is less than about 1 g/ml.

Abstract: Methods which reduce natural stain from teeth are described.